Mpox, formerly known as monkeypox, remains a significant and evolving global health challenge in 2025, with distinct epidemiological patterns observed between Africa and the rest of the world.
Current Global Epidemiology and Virus Variants
Since the initial outbreaks that gained global attention in 2022, mpox has demonstrated a bifurcated pattern of transmission. Outside Africa, the ongoing global outbreak—largely driven by mpox virus clade IIb—has infected over 100,000 people across more than 120 countries, primarily among certain sexual networks. This clade has shown some decline in transmission intensity due to vaccination efforts and public health interventions.
In contrast, the African continent is facing a growing public health crisis driven by clade I variants. Between January 2024 and mid-2025, 26 African countries reported approximately 35,000 confirmed cases and nearly 1,800 deaths, with a particularly high burden in the Democratic Republic of Congo, Sierra Leone, and Malawi. The clade I virus—especially its evolving sub-variant 1a with APOBEC3 mutations—may be more adept at spreading in communities, including rural areas, children, and healthcare workers. These mutations raise concerns about increased transmissibility and potential challenges to control efforts.
Clinical Features and Risks
Mpox is a zoonotic infectious disease caused by an orthopoxvirus. Symptoms include fever, headache, muscle aches, swollen lymph nodes, and a characteristic rash that progresses through blistering and scabbing phases. While many cases are mild and resolve without treatment, severe illness can occur, notably in children, pregnant women, and immunocompromised individuals. The recent epidemic waves underscore higher mortality associated with clade I infections, particularly in Central Africa where case fatality rates have been estimated near 3%.
Response Measures and Treatment Options
In August 2024, the World Health Organization (WHO) formally declared the mpox epidemic a Public Health Emergency of International Concern (PHEIC), emphasizing the urgency for coordinated surveillance, research, and control strategies. Vaccines originally developed for smallpox have demonstrated cross-protection against mpox, and targeted vaccination campaigns remain central in outbreak response, although vaccine availability is uneven, especially in Africa.
No specific antiviral treatments are universally approved for mpox, but certain agents such as tecovirimat, cidofovir, and ribavirin have shown potential efficacy in clinical or laboratory settings and are considered for compassionate use. Supportive care continues to be the mainstay of treatment for most patients. Researchers are actively studying viral genomics and immune responses to better understand disease mechanisms and improve therapeutics.
Implications for Public Health and Future Directions
The divergent epidemiology of mpox highlights critical challenges in global health equity. While many high-income countries have seen reductions in clade IIb transmission due to vaccination and public awareness, African nations are contending with intensifying outbreaks caused by a more virulent clade I variant. This disparity necessitates urgent investment in healthcare infrastructure, access to vaccines and therapeutics, and community engagement tailored to local contexts.
Enhanced surveillance and genomic monitoring are essential to track viral mutations that may affect transmissibility or severity. Additionally, understanding the role of zoonotic reservoirs remains a priority to prevent future outbreaks. Public health messaging should continue to emphasize recognition of symptoms, avoiding contact with potentially infected animals, and seeking timely medical care.
For the medical community, this ongoing epidemic underscores the importance of vigilance for emerging infectious diseases and the need for robust global collaboration in research and resource allocation. For the public, awareness of mpox symptoms and transmission routes is vital to reducing spread and ensuring early diagnosis.
Providing clear, evidence-based information about mpox and supporting equitable access to prevention and treatment resources remain key public health goals as the world confronts this persistent threat.
For comprehensive updates and expert insights on infectious diseases including mpox, readers can refer to resources provided by the World Health Organization and CDC. Within Globally Pulse, explore more detailed coverage on global viral outbreaks and health responses in the Health section.
